BioCentury
ARTICLE | Clinical News

XEN-D0501: Phase IIa started

February 17, 2014 8:00 AM UTC

Ario began a double-blind, placebo-controlled, crossover, U.K. Phase IIa trial to evaluate oral XEN-D0501 for 14 days in about 22 patients. The company is also planning to start a Phase II trial of XE...